| 1 |
Novakova Z, Milosevic M, Kutil Z, Ondrakova M, Havlinova B, Kasparek P, Sandoval-Acuña C, Korandova Z, Truksa J, Vrbacky M, Rohlena J, Barinka C. Generation and characterization of human U-2 OS cell lines with the CRISPR/Cas9-edited protoporphyrinogen oxidase IX gene. Sci Rep 2022;12:17081. [PMID: 36224252 DOI: 10.1038/s41598-022-21147-x] [Reference Citation Analysis]
|
| 2 |
Lupica A, Di Stefano V, Gagliardo A, Iacono S, Pignolo A, Ferlisi S, Torrente A, Pagano S, Gangitano M, Brighina F. Inherited Neuromuscular Disorders: Which Role for Serum Biomarkers? Brain Sci 2021;11:398. [PMID: 33801069 DOI: 10.3390/brainsci11030398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 3 |
Kaftory R, Edel Y, Snast I, Lapidoth M, Mamet R, Elis A, Hodak E, Levi A. Greater disease burden of variegate porphyria than hereditary coproporphyria: An Israeli nationwide study of neurocutaneous porphyrias. Mol Genet Metab Rep 2021;26:100707. [PMID: 33489763 DOI: 10.1016/j.ymgmr.2021.100707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Zhao L, Wang X, Zhang X, Liu X, Ma N, Zhang Y, Zhang S. Therapeutic strategies for acute intermittent porphyria. Intractable Rare Dis Res 2020;9:205-16. [PMID: 33139979 DOI: 10.5582/irdr.2020.03089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Ma Y, Teng Q, Zhang Y, Zhang S. Acute intermittent porphyria: focus on possible mechanisms of acute and chronic manifestations. Intractable Rare Dis Res 2020;9:187-95. [PMID: 33139977 DOI: 10.5582/irdr.2020.03054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Ma L, Tian Y, Peng C, Zhang Y, Zhang S. Recent advances in the epidemiology and genetics of acute intermittent porphyria. Intractable Rare Dis Res 2020;9:196-204. [PMID: 33139978 DOI: 10.5582/irdr.2020.03082] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 7 |
Yang Y, Chen X, Wu H, Peng H, Sun W, He B, Yuan Z. A novel heterozygous mutation in the HMBS gene in a patient with acute intermittent porphyria and posterior reversible encephalopathy syndrome. Mol Med Rep 2020;22:516-24. [PMID: 32377710 DOI: 10.3892/mmr.2020.11117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Bustos J, Vargas L, Quintero R. Acute intermittent porphyria: A case report. Biomedica 2020;40:14-9. [PMID: 32220159 DOI: 10.7705/biomedica.4767] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 9 |
Esteve-Valverde E, Tapiz-Reula A, Ruiz D, Alijotas-Reig J. Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria. Rheumatol Int 2020;40:777-83. [PMID: 31865445 DOI: 10.1007/s00296-019-04500-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 10 |
Chacko B, Culp ML, Bloomer J, Phillips J, Kuo YF, Darley-Usmar V, Singal AK. Feasibility of cellular bioenergetics as a biomarker in porphyria patients. Mol Genet Metab Rep 2019;19:100451. [PMID: 30740306 DOI: 10.1016/j.ymgmr.2019.100451] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 11 |
Blaha T, Nigwekar S, Combs S, Kaw U, Krishnappa V, Raina R. Dermatologic manifestations in end stage renal disease. Hemodial Int 2019;23:3-18. [PMID: 30520561 DOI: 10.1111/hdi.12689] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 12 |
Granata F, Mendez M, Brancaleoni V, Castelbon FJ, Graziadei G, Ventura P, Di Pierro E. Molecular characterization, by digital PCR analysis of four HMBS gene mutations affecting the ubiquitous isoform of Porphobilinogen Deaminase (PBGD) in patients with Acute Intermittent Porphyria (AIP). Mol Genet Metab 2018;125:295-301. [PMID: 30201327 DOI: 10.1016/j.ymgme.2018.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 13 |
Cardinali DP. Clinical Implications of the Enlarged Autonomic Nervous System. Autonomic Nervous System 2018. [DOI: 10.1007/978-3-319-57571-1_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 14 |
Júnior VRS, Lemos VMV, Feitosa IML, Florencio R, Correia CWB, Fontes LBC, Costa MFH, Correia MCB. Effect of Menstrual Cycle on Acute Intermittent Porphyria. Child Neurol Open 2017;4:2329048X17736170. [PMID: 29094055 DOI: 10.1177/2329048X17736170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Bonavia A, Pachuski J, Bezinover D. Perioperative Anesthetic Management of Patients Having Liver Transplantation for Uncommon Conditions. Semin Cardiothorac Vasc Anesth 2018;22:197-210. [PMID: 28922972 DOI: 10.1177/1089253217732129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 16 |
Kumar S, Bhalla A, Sharma N, Dhibar DP, Kumari S, Varma S. Clinical, Biochemical Characteristics and Hospital Outcome of Acute Intermittent Porphyria Patients: A Descriptive Study from North India. Ann Indian Acad Neurol 2017;20:263-9. [PMID: 28904459 DOI: 10.4103/aian.AIAN_91_17] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 17 |
Abdelmaksoud A. Anti-HCV for porphyria cutanea tarda. Dermatol Ther 2017;30. [PMID: 28133909 DOI: 10.1111/dth.12466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
